Following the COVID-19 pandemic, increases were seen in the global disease burden of malaria, depressive disorders, and anxiety disorders.

Black patients with opioid use disorder are less likely to receive referrals to outpatient treatment for opioid use disorder.

The design of recruitment tools for clinical trials impacts rates of enrollment, with higher enrollment seen for shorter letters.